These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26426443)

  • 21. Does time-intensive ERP attenuate the negative impact of comorbid personality disorders on the outcome of treatment-resistant OCD?
    Dèttore D; Pozza A; Coradeschi D
    J Behav Ther Exp Psychiatry; 2013 Dec; 44(4):411-7. PubMed ID: 23770674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
    Oulis P; Mourikis I; Konstantakopoulos G
    Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
    Torp NC; Dahl K; Skarphedinsson G; Compton S; Thomsen PH; Weidle B; Hybel K; Valderhaug R; Melin K; Nissen JB; Ivarsson T
    J Am Acad Child Adolesc Psychiatry; 2015 Mar; 54(3):200-207.e1. PubMed ID: 25721185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients.
    Laurito LD; Loureiro CP; Dias RV; Vigne P; de Menezes GB; Freire RC; Stangier U; Fontenelle LF
    Psychiatry Res; 2018 Apr; 262():237-245. PubMed ID: 29475102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
    Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
    J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder.
    Grant JE; Mancebo MC; Weinhandl E; Odlaug BL; Eisen JL; Rasmussen SA
    Int Clin Psychopharmacol; 2013 Jul; 28(4):200-5. PubMed ID: 23587985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
    Stein DJ; Bouwer C; Hawkridge S; Emsley RA
    J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.
    Stewart SE; Jenike EA; Hezel DM; Stack DE; Dodman NH; Shuster L; Jenike MA
    J Clin Psychopharmacol; 2010 Feb; 30(1):34-9. PubMed ID: 20075645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.
    Marazziti D; Pfanner C; Dell'Osso B; Ciapparelli A; Presta S; Corretti G; Di Nasso E; Mungai F; Dell'Osso L
    J Psychopharmacol; 2005 Jul; 19(4):392-4. PubMed ID: 15982994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extinction retention and fear renewal in a lifetime obsessive-compulsive disorder sample.
    McLaughlin NC; Strong D; Abrantes A; Garnaat S; Cerny A; O'Connell C; Fadok R; Spofford C; Rasmussen SA; Milad MR; Greenberg BD
    Behav Brain Res; 2015 Mar; 280():72-7. PubMed ID: 25446749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.